Autopsy report · NCT02358863

Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

“Issues with recruitment.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 9 months before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 1 year 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Georgetown University

Sponsor type

University, hospital or other

Conditions

Esophageal Cancer; Gastric Cancer

Interventions

Modified FOLFOX6; Docetaxel/Capecitabine; Cisplatin/Irinotecan; Cisplatin/Docetaxel; IRI/EPI; EPI/Docetaxel

Participants

13

Sites

1

Countries

United States

Trials that died the same way

• The Cancer Pain and Unmet Needs Study
  “Recruitment issues.” (97% match in meaning)
• Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer
  “Problems of recruitment” (91% match in meaning)
• Study of the Impact of Non-pharmacological Techniques on Cognitive Complaints in Cancer Patients
  “Problems with recruitment” (90% match in meaning)
• Sensitivity of Frequent SARS-CoV-2 (COVID-19) Rapid Antigen Testing Regimen
  “Difficulty with recruitment.” (90% match in meaning)
• Efficacy of Angiographic Embolization vs Non-embolization of Moderate/Poor Vascularized Vertebral Metastases on Intraoperative Bleeding During Surgery Decompression and Vertebral Stabilization.
  “Difficulties in recruitment.” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.